Cur

0300

Attorney's Docket No. <u>018995-452</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 0 7 2002

e Patent Application of

ishizumi NISHIMUTA et al

pplication No.: 10/046,575

Filed: January 16, 2002

For: EXTERNAL PREPARATION FOR SKIN

DISEASES CONTAINING NITROIMIDAZOLE Group Art Unit: Unknown

Examiner: Unknown

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X]	No additional	fee for	submission	of an	IDS	is required.
-----	---------------	---------	------------	-------	-----	--------------

- [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: June 7, 2002

Silsan M

Registration No. 40,373



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Nishizumi NISHIMUTA et al.) Group Art Unit: Unknown
Application No.: 10/046,575) Examiner: Unknown
Filed: January 16, 2002))
For: EXTERNAL PREPARATION FOR SKIN DISEASES CONTAINING NITROIMIDAZOLE))))

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

NON-PATENT DOCUMENTS

- 1. GOTO et al., "Suppressive Effect of Topically Applied CX-6595, a Novel Diaminouracil Derivative, on the Contact Hypersensitivity Reaction in Various Animal Models", *International Archives of Allergy and Immunology*, August 28, 2000, pp. 341-348, vol. 123, Basel, Switzerland.
- 2. ANITEX Vol. 10, No. 3, pp. 155-161
- 3. "Cyclosporin ointment for psoriasis and atopic dermatitis," *The Lancet*, May 2, 1992, p. 1120, vol. 339.
- 4. YAKYOKU, 1996, pp. 31-35, vol. 47, no. 8.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

Information Disclosure Statement Application Serial No. <u>10/046,575</u> Attorney's Docket No. <u>018995-452</u> Page 2

To assist the Examiner, the listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: XILLAN Dad

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: June 7, 2002